JD Supra May 24, 2022
The healthcare industry is highly regulated, and as such, private equity firms and dealmakers in the industry must pay immense attention to regulatory compliance, particularly with regard to their portfolio companies. The government’s reach may not stop at a firm’s portfolio company or even its executives, as we have seen in situations like this one where a private equity firm was fined $25 million for oversight failures related to false claims made by its portfolio company.
In this environment, private equity firms and the boards of their portfolio companies need to get out in front of potential regulatory compliance issues. Below are five questions private equity firms should be asking their healthcare portfolio companies right now.
(1) Do you have...
Today's Sponsors
Today's Sponsor